Seres Therapeutics Q4/FY2023: VOWST net sales $10.4M Q4, $19.6M YTD; net loss narrows to $113.7M

Seres Therapeutics, Inc.

Net loss of $113.7M for FY2023 versus $250.2M prior year; Q4 net loss $41.2M vs $68.8M.
VOWST net sales $10.4M in Q4, $19.6M since June launch; 2,833 enrollment forms, 2,015 new patient starts.
Restructuring expected to save $75-85M annually; cash and equivalents $128.0M at year-end.
SER-155 Phase 1b Cohort 2 data readout anticipated in Q3 2024; Fast Track designation awarded.
Appointed Marella Thorell as EVP/CFO following retirement of David Arkowitz.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Seres Therapeutics, Inc. reported quarter and year ended December 31, 2023 results: revenue $10.4 million, net income $41.2 million.

Period: quarter and year ended December 31, 2023
Revenue: $10.4 million
Net income: $41.2 million
Result: reported results

Exact text from the filing

Seres reported a net loss of $41.2 million for the fourth quarter of 2023, as compared to a net loss of $68.8 million for the same period in 2022. Net sales of VOWST for the fourth quarter and full year 2023, were $10.4 million and $19.6 million, respectively

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-058584

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.